Cancer
Geneva drives cancer research to improve the quality of life of service members, veterans, their families, and the global community by decreasing the burden of cancer.
Geneva collaborates with a multitude of academic and industry stakeholders in oncology research at federal laboratories and military treatment facilities including: National Cancer Institute, Uniformed Services University, and Madigan Army Research Center.
Performance Capabilities
Driving Cutting-Edge Science
Geneva researchers have experience in developing biologics and cancer therapeutics, with expertise in areas including:
- Basic research
- Bioinformatic analysis
- Biomarker discovery
- Bioprinting
- Cancer biology
- Clinical cancer drugs
- Clinical trials
- Diagnostic testing
- Genome-wide analysis
- Immunotherapy
- IND support
- Personalized medicine
- Population-based research
- Preclinical research
- Prognostic markers
- Translational research
Geneva Expertise
Featured Researcher
Curtis Harris, MD
Dr. Harris, a scientist at NCI, has conducted research that has spanned more than half a century, making significant breakthroughs in cancer research.
DECAMP Consortium
The Detection of Early Lung Cancer Among Military Personnel (DECAMP) Consortium is a multidisciplinary and translational research program intended to improve early detection of lung cancer through non-invasive biomarkers and improved screening. DECAMP 1 and 2 studies are funded through the DoD Lung Cancer Research Program, Johnson and Johnson Inc., and Novartis Biomedical Research Institutes.
Read More
Research Indications
Geneva has diverse experience in managing oncology programs in areas including:
Bladder Cancer
Brain Metastases
Breast Cancer
Childhood Cancers
Follicular Lymphoma
Glioblastoma
Head and Neck Cancer
Leukemia
Lung Cancer
Mantle Cell Lymphoma
Metastatic Colorectal Cancer
Neoplasms
Neuroblastoma
Non-Hodgkin Lymphoma
Non-Small Cell Lung Cancer
Ovarian Cancer
Prostate Cancer
Rare Cancers
Small Cell Carcinoma
Tumors